STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Caligan Partners and David Johnson Disclose 3.34M EOLS Shares (5.2%)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Caligan Partners LP and its managing partner David Johnson filed a Schedule 13G reporting shared beneficial ownership of 3,341,970 shares of Evolus, Inc. common stock, representing 5.2% of the class based on 64,475,589 shares outstanding as of May 2, 2025. The reporting persons state the shares are held by Caligan Partners Master Fund LP and a managed account and are owned in the ordinary course of business, not to influence control of the company. Caligan is organized in Delaware and Mr. Johnson is a U.S. citizen. Principal business address for the filers is 780 Third Avenue, 30th Floor, New York, NY 10017.

Positive

  • Disclosure of >5% stake provides transparency on ownership concentration
  • Filed as Schedule 13G, indicating the position is represented as passive and held in the ordinary course
  • Detailed ownership basis (3,341,970 shares and the 64,475,589 share outstanding figure) gives precise percentage context

Negative

  • None.

Insights

TL;DR A single investment manager reports a modest, disclosed stake just above 5%, filed under passive Schedule 13G rules.

The filing shows Caligan and David Johnson hold a 5.2% position via the Caligan Fund and a managed account, with 3,341,970 shares reported as shared voting and dispositive power. Because this is a Schedule 13G and the certifying language states the position is held in the ordinary course and not to influence control, the position is presented as passive rather than an activist stake. The reported base of 64,475,589 outstanding shares gives clear context for the percentage. For investors, this is a material disclosure of ownership concentration but not a signal of attempted control or change in governance.

TL;DR Disclosure indicates passive holdings with shared voting rights; not a control intent filing.

The statement includes the required certification that the securities were acquired and are held in the ordinary course of business and not for purposes of changing or influencing control. Reporting classification codes list Caligan as an investment adviser and private fund ("IA, PN") and Mr. Johnson as a hedge/individual participant ("HC, IN"), which aligns with common fund-manager reporting. Signatures by Mr. Johnson as both managing partner and individually complete the joint filing. This satisfies regulatory transparency for a >5% shareholder without implying governance action.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Caligan Partners LP
Signature:/s/ David Johnson
Name/Title:David Johnson, Managing Partner
Date:08/14/2025
David Johnson
Signature:/s/ David Johnson
Name/Title:David Johnson, Individually
Date:08/14/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake in Evolus (EOLS) does Caligan Partners LP report?

Caligan Partners LP and David Johnson report beneficial ownership of 3,341,970 shares, equal to 5.2% of Evolus common stock.

Is the Caligan position in EOLS filed as active or passive?

The position is filed on Schedule 13G with a certification stating the shares are held in the ordinary course of business and not to change or influence control, indicating a passive position.

What share count was used to calculate the 5.2% for EOLS?

The percentage is calculated using 64,475,589 shares outstanding as of May 2, 2025, per the companys quarterly report.

Who are the reporting persons and where are they located?

The filers are Caligan Partners LP (a Delaware limited partnership) and David Johnson (Managing Partner). Their principal business address is 780 Third Avenue, 30th Floor, New York, NY 10017.

Did the filers assert any intent to influence company control?

No. The filing includes a certification that the securities were not acquired or held for the purpose of changing or influencing the issuers control.
Evolus

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Latest SEC Filings

EOLS Stock Data

447.90M
53.53M
11.81%
91.06%
17.98%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH